Insider · CIK 0001435183
Garheng Kong
Files at LH (LABORATORY CORP OF AMERICA HOLDINGS), XERS (Xeris Biopharma Holdings, Inc.). First filing -, latest -.
In brief
Garheng Kong files SEC Form 4 as director at LH (LABORATORY CORP OF AMERICA HOLDINGS), and also at XERS (Xeris Biopharma Holdings, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Garheng Kong has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 14 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 4, 2026 | XERS Xeris Biopharma Holdings, Inc. | AGrant or award Common Stock | +24,193 | $0.00 | $0 | 238,337 | Jun 5, 2026 |
| Jun 4, 2026 | XERS Xeris Biopharma Holdings, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +32,996 | $6.15 | $203k | 32,996 | Jun 5, 2026 |
| Feb 11, 2026 | LH LABORATORY CORP OF AMERICA HOLDINGS | MOption exercise Common Stock | +897 | - | - | 13,739 | Feb 13, 2026 |
| Feb 11, 2026 | LH LABORATORY CORP OF AMERICA HOLDINGS | MOption exercise Restricted Stock Unitderivative | -897 | $0.00 | $0 | 773 | Feb 13, 2026 |
| Feb 10, 2026 | LH LABORATORY CORP OF AMERICA HOLDINGS | AGrant or award Restricted Stock Unitderivative | +773 | $0.00 | $0 | 1,670 | Feb 12, 2026 |
| Jun 4, 2025 | XERS Xeris Biopharma Holdings, Inc. | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 214,144 | Jun 4, 2025 |
| Feb 11, 2025 | LH LABORATORY CORP OF AMERICA HOLDINGS | AGrant or award Restricted Stock Unitderivative | +897 | $0.00 | $0 | 897 | Feb 13, 2025 |
| Feb 6, 2025 | LH LABORATORY CORP OF AMERICA HOLDINGS | MOption exercise Common Stock | +944 | - | - | 12,842 | Feb 10, 2025 |
| Feb 6, 2025 | LH LABORATORY CORP OF AMERICA HOLDINGS | MOption exercise Restricted Stock Unitderivative | -944 | $0.00 | $0 | 0 | Feb 10, 2025 |
| Jun 5, 2024 | XERS Xeris Biopharma Holdings, Inc. | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 164,144 | Jun 5, 2024 |
| Mar 15, 2024 | XERS Xeris Biopharma Holdings, Inc. | JOther Common Stock | +6,474 | - | - | 114,144 | Apr 1, 2024 |
| Feb 7, 2024 | LH LABORATORY CORP OF AMERICA HOLDINGS | MOption exercise Common Stock | +947 | - | - | 11,898 | Feb 8, 2024 |
| Feb 6, 2024 | LH LABORATORY CORP OF AMERICA HOLDINGS | AGrant or award Restricted Stock Unitderivative | +944 | $0.00 | $0 | 1,891 | Feb 8, 2024 |
| Feb 7, 2024 | LH LABORATORY CORP OF AMERICA HOLDINGS | MOption exercise Restricted Stock Unitderivative | -947 | $0.00 | $0 | 944 | Feb 8, 2024 |
Questions about Garheng Kong
Answered from the filings on this page, as of the latest one.
Is Garheng Kong buying or selling?
Garheng Kong has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Garheng Kong's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Garheng Kong has 0.
Where does Garheng Kong file Form 4?
Garheng Kong has filed Form 4 at LH (LABORATORY CORP OF AMERICA HOLDINGS); XERS (Xeris Biopharma Holdings, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.